Short-term outcomes of Mitomycin-C augmented phaco-trabeculectomy using subconjunctival injections versus soaked sponges: a randomized controlled trial.
Chakrabarty Sabyasachi, Kader Mohideen Abdul, Maheshwari Devendra, Pillai Madhavi Ramanatha, Chandrashekharan Shivkumar, Ramakrishnan Rengappa
AI Summary
This study found Mitomycin-C injections during phaco-trabeculectomy achieved lower eye pressure and fewer medications than sponges, offering a safer, more effective glaucoma surgery option.
Abstract
Objectives
To determine whether subconjunctival Mitomycin-C (MMC) injections are as safe and effective as sponge-soaked MMC in phaco-trabeculectomy.
Methods
This prospective, randomized, interventional study was conducted on consecutive patients with visually significant cataract and an uncontrolled primary open-angle glaucoma. One hundred thirty-nine patients were recruited but 15 were ineligible for analysis. The patients were randomized into a sponge/injection group. All participants received a twin-site phaco-trabeculectomy. They were followed up on days 1, 15, 30, 3 months and 6 months post-operatively. A p-value < 0.05 was considered significant.
Interventions
Participants in the sponge group received an augmentation of their phaco-trabeculectomy with sponges soaked in a mixture of 0.04% MMC and 2% preservative-free Lignocaine in a 1:1 ratio, placed in the subconjunctival space for four minutes. Participants in the injection group received the same mixture as a subconjunctival injection, after surgical draping.
Results
There were 62 patients in each group. The groups had no significant differences in their baseline characteristics. The mean IOP at 6 months was significantly lower in the injection group (14.8 ± 3.7 mm Hg) than in the sponge group (17.1 ± 6.4 mm Hg) (p = 0.02). There was no notable difference in the complications or the final post-operative visual outcome but a significantly greater number of patients in the sponge arm required removal of the releasable suture (p = 0.001) and additional anti-glaucoma medications (p = 0.04) at six months post-operatively.
Conclusions
Subconjunctival MMC achieves a lower IOP with fewer anti-glaucoma medications than sponge-soaked MMC at six months for twin-site phaco-trabeculectomy in primary open-angle glaucoma with no additional risks.
MeSH Terms
Shields Classification
Key Concepts5
Subconjunctival Mitomycin-C (MMC) injection achieved a lower mean intraocular pressure (IOP) of 14.8 ± 3.7 mm Hg at 6 months compared to sponge-soaked MMC (17.1 ± 6.4 mm Hg, p = 0.02) in patients undergoing twin-site phaco-trabeculectomy for primary open-angle glaucoma.
Subconjunctival Mitomycin-C (MMC) injection resulted in fewer anti-glaucoma medications at 6 months post-operatively compared to sponge-soaked MMC (p = 0.04) in patients undergoing twin-site phaco-trabeculectomy for primary open-angle glaucoma.
A significantly greater number of patients in the sponge-soaked Mitomycin-C (MMC) arm required removal of the releasable suture (p = 0.001) at six months post-operatively compared to the subconjunctival MMC injection arm in patients undergoing twin-site phaco-trabeculectomy for primary open-angle glaucoma.
There was no significant difference in complications or final post-operative visual outcome between subconjunctival Mitomycin-C (MMC) injection and sponge-soaked MMC in patients undergoing twin-site phaco-trabeculectomy for primary open-angle glaucoma.
This prospective, randomized, interventional study compared subconjunctival Mitomycin-C (MMC) injections versus sponge-soaked MMC in 124 patients (62 per group) with visually significant cataract and uncontrolled primary open-angle glaucoma undergoing twin-site phaco-trabeculectomy.
Related Articles5
Long-term comparative outcomes of Hydrus versus iStent inject microinvasive glaucoma surgery implants combined with cataract surgery.
Observational StudyTwo-year outcomes of Xen 45 gel stent implantation in patients with open-angle glaucoma: real-world data from the Fight Glaucoma Blindness registry.
Observational StudyTwo-Year Performance and Safety Results of the MINIject Supraciliary Implant in Patients With Primary Open-Angle Glaucoma: Meta-Analysis of the STAR-I, II, III Trials.
Meta-AnalysisLong-Term Outcome After Canaloplasty and Phacocanaloplasty in Primary Open Angle Glaucoma.
Cohort StudyCataract surgery combined with glaucoma surgery.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.